Octreotide pharmacokinetics

Octreotide modestly increases the bioavailability of bromocriptine, whereas bromocriptine does not appear to alter octreotide pharmacokinetics. 

Pharmacokinetics After subcutaneous injection, octreotide is absorbed rapidly and completely from the injection site intravenous and subcutaneous doses were... 

Chanson, P., J. Timsit, and A.G. Harris. 1993. Clinical pharmacokinetics of octreotide. Therapeutic applications in patients with pituitary tumours. Clin. Pharmacokinet. 25 375-391. 

Labar D, Carlier P, et al. Y-DOTA0-D-Phel-Tyr3-octreotide (SMT487). A phase 1 clinical study pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nud Med 2003 30 510-518. 

Wester H-J, Brockman J, Rosch F, et al. (1997). PET-pharmacokinetics of F-octreotide A comparison with Ga-DFO- and Y-DTPA-octreotide. Nucl. Med. Biol. 24 275-286. 

Following a single intragluteal intramuscular injection of microencapsulated octreotide acetate in healthy cholecystectomized subjects, the pharmacokinetic profile of octreotide was characterized by an initial peak of octreotide followed by a sustained release of drug. Plateau concentration was sustained up to day 70, and gradually declined to below the detection limit by day 112. A population covariate pharmacokinetic model was constructed that consisted of two absorption processes, one for immediate-release portion from the surface, unencapsulated drug and another for sustained-release portion from the microencapsulated drug. ... 

Tuvia S, Atsmon J, Teichman S, Katz S, Salama P, PeUed D, et al. Oral octreotide absorption in human subjects comparable pharmacokinetics to parenteral octreotide and effective growth hormone suppression. J Clin Endocrinol Metab 2012 97(7) 2362-9. 

---